Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.37 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10611171 | 0.89 | HSPA5 (0.47) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL14934287 | 0.86 | ACE2 (0.44) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL30743768 | 0.86 | ACE2 (0.44) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL12326734 | 0.82 | KIF11 (0.40) | SMN1; SMN2ALDH1A1POLBAMY1ATDP1 | |
| SCHEMBL25677923 | 0.81 | HSPA5 (0.42) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL1990099 | 0.79 | KLF10 (0.50) | SMN1; SMN2CYP2C19ALDH1A1TYRCYP2D6 | |
| SCHEMBL19565547 | 0.79 | TAAR1 (0.44) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL15130531 | 0.79 | HSPA5 (0.41) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL26853007 | 0.78 | HSPA5 (0.39) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL28959035 | 0.78 | HSPA5 (0.39) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | disclosed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | disclosed |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2021-11-11 | — | — | US | disclosed |
| US-8536195-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130190529-A1 | Fluorine Radiolabelling Process | ISIS INNOVATION LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| US-20130084639-A1 | Bicyclic Derivatives as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-04 | — | — | US | disclosed |
| US-20120308606-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | HSPA5 1476/4885SMN1; SMN2 1/4885CYP2C9 2726/4885 |
| US-20120308606-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | TRPV1, TRPV2, TRPV3 | HSPA5 2440/4885SMN1; SMN2 1855/4885CYP2C9 3851/4885 |
| US-20130190529-A1 | Fluorine Radiolabelling Process | ESRRG, NR5A2, RXFP4 | HSPA5 1584/4885SMN1; SMN2 3263/4885CYP2C9 648/4885 |
| US-20130084639-A1 | Bicyclic Derivatives as Modulators of Ion Channels | KCNJ2, TRPV1, KCNN3 | HSPA5 1236/4885SMN1; SMN2 1162/4885CYP2C9 2533/4885 |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SMN1; SMN2, SNCA, HTT | HSPA5 1476/4885SMN1; SMN2 1/4885CYP2C9 2726/4885 |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | HSPA5 1476/4885SMN1; SMN2 1/4885CYP2C9 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.